Security Snapshot

ADMA BIOLOGICS, INC. - Common Stock (ADMA) Institutional Ownership

CUSIP: 000899104

13F Institutional Holders and Ownership History from Q2 2014 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

341

Shares (Excl. Options)

207,105,771

Price

$9.01

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock
Symbol
ADMA on Nasdaq
Shares outstanding
238,388,839
Price per share
$10.93
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
207,105,771
Total reported value
$1,866,213,260
% of total 13F portfolios
0%
Share change
-11,582,783
Value change
-$362,584,546
Number of holders
341
Price from insider filings
$10.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ADMA - ADMA BIOLOGICS, INC. - Common Stock is tracked under CUSIP 000899104.
  • 341 institutions reported positions in Q1 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 352 to 341 between Q4 2025 and Q1 2026.
  • Reported value moved from $4,014,361,861 to $1,866,213,260.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 341 institutions filings for Q1 2026.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 000899104?
CUSIP 000899104 identifies ADMA - ADMA BIOLOGICS, INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.

Significant Owners of ADMA BIOLOGICS, INC. - Common Stock (ADMA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% $865,732,260 35,907,601 BlackRock, Inc. 31 Mar 2025
VANGUARD CAPITAL MANAGEMENT LLC 5.1% $109,112,479 12,110,153 Vanguard Capital Management 31 Mar 2026
STATE STREET CORP 5.1% +6% $221,519,782 +$11,695,913 12,078,505 +5.6% STATE STREET CORPORATION 30 Jun 2025
Invesco Ltd. 5% -8% $211,308,672 -$19,394,917 11,785,202 -8.4% Invesco Ltd. 31 Dec 2025

As of 31 Mar 2026, 341 institutional investors reported holding 207,105,771 shares of ADMA BIOLOGICS, INC. - Common Stock (ADMA). This represents 87% of the company’s total 238,388,839 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ADMA BIOLOGICS, INC. - Common Stock (ADMA) together control 63% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 36,830,774 +1.4% 0.01% $331,845,274
STATE STREET CORP 5.9% 14,084,205 +3.6% 0% $126,898,687
Capital Research Global Investors 4.7% 11,191,116 +69% 0.02% $100,831,955
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 10,306,871 0% 0% $92,864,908
VANGUARD PORTFOLIO MANAGEMENT LLC 3.7% 8,868,657 0% 0% $79,906,600
Nuveen, LLC 2.6% 6,098,225 +2.9% 0.01% $54,945,008
GEODE CAPITAL MANAGEMENT, LLC 2.4% 5,824,116 -0.12% 0% $52,484,178
CITADEL ADVISORS LLC 2.4% 5,810,642 +282% 0.04% $52,353,885
DIMENSIONAL FUND ADVISORS LP 2.1% 5,005,481 +3.5% 0.01% $45,101,264
AMERICAN CENTURY COMPANIES INC 2% 4,789,011 -7.9% 0.02% $43,148,996
Caligan Partners LP 2% 4,756,511 +58% 3% $42,856,164
Invesco Ltd. 1.7% 4,119,577 -65% 0.01% $37,117,389
MILLENNIUM MANAGEMENT LLC 1.4% 3,434,449 +413% 0.02% $30,944,385
Point72 Asset Management, L.P. 1.4% 3,288,757 +735% 0.05% $29,631,701
B Group, Inc. 1.3% 3,207,542 +31% 21% $28,899,953
JANE STREET GROUP, LLC 1.3% 3,051,943 +564% 0.03% $27,498,007
GOLDMAN SACHS GROUP INC 1.2% 2,803,530 +162% 0% $25,259,806
MORGAN STANLEY 1% 2,434,379 +25% 0% $21,933,757
FRANKLIN RESOURCES INC 0.98% 2,344,899 -16% 0.01% $21,127,540
Ranger Investment Management, L.P. 0.96% 2,283,810 -0.74% 1.5% $20,577,128
NORTHERN TRUST CORP 0.96% 2,277,312 +0.46% 0% $20,518,581
PRICE T ROWE ASSOCIATES INC /MD/ 0.93% 2,216,285 +2.6% 0% $19,970,000
UBS Group AG 0.9% 2,150,276 -53% 0% $19,373,987
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.88% 2,095,772 -7.2% 0% $18,882,906
TWO SIGMA INVESTMENTS, LP 0.88% 2,092,133 +315% 0.02% $18,850,118

Institutional Holders of ADMA BIOLOGICS, INC. - Common Stock (ADMA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 207,105,771 $1,866,213,260 -$362,584,546 $9.01 341
2025 Q4 220,099,164 $4,014,361,861 +$38,656,321 $18.24 352
2025 Q3 218,105,635 $3,198,245,207 +$72,502,856 $14.66 359
2025 Q2 210,797,270 $3,837,973,056 +$78,904,738 $18.21 367
2025 Q1 205,274,525 $4,072,982,276 +$76,450,592 $19.84 342
2024 Q4 203,746,953 $3,496,535,119 -$114,107,061 $17.15 316
2024 Q3 207,372,865 $4,143,053,602 +$165,315,203 $19.99 300
2024 Q2 181,187,738 $2,025,731,155 +$84,927,207 $11.18 251
2024 Q1 174,472,998 $1,151,565,465 +$38,336,177 $6.60 213
2023 Q4 169,158,841 $764,627,025 -$2,944,733 $4.52 184
2023 Q3 171,151,086 $612,714,569 +$20,026,265 $3.58 188
2023 Q2 165,493,139 $610,610,254 +$2,418,775 $3.69 178
2023 Q1 165,334,603 $547,246,486 +$39,069,063 $3.31 161
2022 Q4 152,691,438 $592,428,828 +$84,016,367 $3.88 160
2022 Q3 129,844,191 $315,525,087 +$25,706,332 $2.43 126
2022 Q2 119,212,509 $236,039,706 +$28,768,170 $1.98 106
2022 Q1 104,891,672 $189,908,374 +$15,200,552 $1.83 101
2021 Q4 97,211,593 $137,058,638 +$69,617,810 $1.41 79
2021 Q3 41,605,720 $47,012,568 -$1,898,278 $1.13 65
2021 Q2 42,881,498 $68,611,517 -$9,321,193 $1.60 77
2021 Q1 48,542,943 $85,432,065 +$4,580,090 $1.76 99
2020 Q4 45,108,342 $87,965,210 -$3,255,262 $1.95 88
2020 Q3 46,229,823 $110,365,108 -$6,638,253 $2.39 89
2020 Q2 48,795,314 $143,056,287 +$1,125,669 $2.93 95
2020 Q1 48,452,749 $139,501,972 +$45,105,921 $2.88 90
2019 Q4 32,462,778 $129,848,396 -$5,342,106 $4.00 74
2019 Q3 37,184,714 $165,464,669 +$10,136,847 $4.45 71
2019 Q2 35,036,040 $135,582,245 +$49,523,348 $3.87 67
2019 Q1 22,292,511 $84,489,596 -$8,434,826 $3.79 54
2018 Q4 24,691,538 $57,976,000 -$3,589,136 $2.39 49
2018 Q3 26,643,107 $165,449,000 +$8,758,819 $6.21 56
2018 Q2 25,531,842 $115,150,787 +$41,337,517 $4.51 53
2018 Q1 16,954,991 $77,991,000 -$211,472 $4.60 34
2017 Q4 17,028,282 $54,659,000 +$27,531,457 $3.21 23
2017 Q3 8,453,450 $26,039,000 -$2,115,756 $3.08 17
2017 Q2 8,911,060 $33,198,000 -$1,175,766 $3.70 19
2017 Q1 9,228,077 $45,033,000 -$611,446 $4.88 17
2016 Q4 9,372,549 $47,987,000 -$550,899 $5.12 17
2016 Q3 9,476,278 $68,659,000 +$188,653 $7.24 18
2016 Q2 9,523,198 $57,439,000 +$6,745,061 $5.95 27
2016 Q1 8,389,293 $67,868,000 -$263,290 $8.09 21
2015 Q4 8,422,364 $67,999,000 -$508,297 $8.07 24
2015 Q3 7,050,136 $58,941,000 +$163,431 $8.36 23
2015 Q2 3,421,139 $31,680,000 +$720,804 $9.26 22
2015 Q1 6,949,700 $32,778,360 +$9,198,949 $9.80 18
2014 Q4 2,367,783 $26,447,585 +$14,273,703 $11.17 11
2014 Q3 776,863 $8,002,000 +$1,130,613 $10.30 1
2014 Q2 667,099 $6,504,000 +$6,504,000 $9.75 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .